Evaluation of cytochrome P450-mediated drug–drug interactions based on the strategies recommended by regulatory authorities

By Kosugi Yohei   Hirabayashi Hideki   Igari Tomoko   Fujioka Yasushi   Hara Yoko   Okuda Teruaki   Moriwaki Toshiya  

Xenobiotica, Vol. 42, Iss. 2, 2012-02 ,pp. : 127-138

Informa Healthcare

Access to resources Recommend Favorite

Drug-drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes

By Kanayama N.   Kanari C.   Masuda Y.   Ohmori S.   Ooie T.  

Xenobiotica, Vol. 37, Iss. 2, 2007-02 ,pp. : 139-154

Informa Healthcare

Access to resources Recommend Favorite

Cytochrome P450 2C11: Escherichia coli Expression, Purification, Functional Characterization, and Mechanism-Based Inactivation of the Enzyme

By Licad-Coles E.   He K.   Yin H.   Correia M.A.  

Archives of Biochemistry and Biophysics, Vol. 338, Iss. 1, 1997-02 ,pp. : 35-42

Elsevier

Access to resources Recommend Favorite

Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid

By Melet A.   Assrir N.   Jean P.   Pilar Lopez-Garcia M.   Marques-Soares C.   Jaouen M.   Dansette P.M.   Sari M-A.   Mansuy D.  

Archives of Biochemistry and Biophysics, Vol. 409, Iss. 1, 2003-01 ,pp. : 80-91

Elsevier

Access to resources Recommend Favorite

In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P₄₅₀ enzyme identification, inhibition, and induction studies

By Li Yan   Zhou Diansong   Ferguson Stephen S.   Dorff Peter   Simpson Thomas R.   Grimm Scott W.  

Xenobiotica, Vol. 40, Iss. 11, 2010-11 ,pp. : 721-729

Informa Healthcare

Access to resources Recommend Favorite